- Home
- BLX vs DYN Comparison
BLX vs DYN Comparison
Compare BLX & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLX
- DYN
- Stock Information
- Founded
- BLX 1977
- DYN 1984
- Country
- BLX Panama
- DYN United States
- Employees
- BLX N/A
- DYN N/A
- Industry
- BLX Commercial Banks
- DYN Medicinal Chemicals and Botanical Products
- Sector
- BLX Finance
- DYN Health Care
- Exchange
- BLX Nasdaq
- DYN Nasdaq
- Market Cap
- BLX 1.4B
- DYN 1.3B
- IPO Year
- BLX N/A
- DYN 2020
- Fundamental
- Price
- BLX $41.17
- DYN $14.70
- Analyst Decision
- BLX
- DYN Strong Buy
- Analyst Count
- BLX 0
- DYN 13
- Target Price
- BLX N/A
- DYN $45.92
- AVG Volume (30 Days)
- BLX 103.5K
- DYN 2.0M
- Earning Date
- BLX 07-22-2025
- DYN 05-08-2025
- Dividend Yield
- BLX 6.10%
- DYN N/A
- EPS Growth
- BLX 13.55
- DYN N/A
- EPS
- BLX 5.60
- DYN N/A
- Revenue
- BLX $289,499,000.00
- DYN N/A
- Revenue This Year
- BLX $13.23
- DYN N/A
- Revenue Next Year
- BLX $7.79
- DYN N/A
- P/E Ratio
- BLX $7.30
- DYN N/A
- Revenue Growth
- BLX 13.37
- DYN N/A
- 52 Week Low
- BLX $27.37
- DYN $6.36
- 52 Week High
- BLX $42.88
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- BLX 57.69
- DYN 72.20
- Support Level
- BLX $40.45
- DYN $13.14
- Resistance Level
- BLX $41.90
- DYN $12.34
- Average True Range (ATR)
- BLX 0.70
- DYN 0.79
- MACD
- BLX -0.08
- DYN 0.23
- Stochastic Oscillator
- BLX 71.48
- DYN 91.82
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.